Related Experiment Video
Updated: Feb 2, 2026

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
Published on: January 7, 2019
ErbB4 acts as a suppressor in colitis and its associated carcinoma by negatively regulating cholesterol metabolism
Hengli Ni1, Lin Chen2,3, Liming Song2,4
1Department of Pathology, Medical College of Soochow University, Soochow University, Suzhou, People's Republic of China.
Abstract:
Previously we reported that ErbB4 played a protective role in chronic liver injury and hepatocellular carcinoma. Herein, we examined the role of ErbB4 in the development of colitis-associated cancer (CAC) in ErbB4 knockout mice models, in vitro cell lines and clinical samples. We found that ErbB4 deficiency may lead to more severe inflammation, slower recovery and the development of CAC. Further, loss of ErbB4 could activate Kras by upregulating rate-limiting enzymes in cholesterol metabolism pathway through interacting with the transcription factor Srebf1. In clinic samples, ErbB4 is downregulated in colonic tissues from patients with Crohn's disease. And data from The Cancer Genome Atlas also showed significant negative correlation between ErbB4 and several cholesterol metabolic enzymes. In summary, our study uncovers ErbB4 as a protector in the development of CAC, for its loss could activate Kras by upregulating cholesterol metabolism.
Insights
The study found that ErbB4 protects against colitis-associated cancer (CAC). Its loss activates Kras by upregulating cholesterol metabolism, worsening inflammation and cancer development.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- ErbB4 (Erb-B2 receptor tyrosine kinase 4) has shown protective effects in liver injury and cancer.
- Colitis-associated cancer (CAC) is a significant health concern with complex underlying mechanisms.
Purpose of the Study:
- To investigate the role of ErbB4 in the development of colitis-associated cancer (CAC).
- To elucidate the molecular mechanisms by which ErbB4 deficiency influences CAC progression.
Main Methods:
- Utilized ErbB4 knockout mice models to study CAC development.
- Employed in vitro cell line experiments and analysis of clinical samples.
- Investigated the interaction between ErbB4, Kras, Srebf1, and cholesterol metabolism pathways.
Main Results:
- ErbB4 deficiency exacerbated inflammation, impaired recovery, and promoted CAC development.
- Loss of ErbB4 led to Kras activation via upregulation of cholesterol metabolism enzymes, mediated by Srebf1.
- ErbB4 was found to be downregulated in Crohn's disease colonic tissues and negatively correlated with cholesterol metabolic enzymes in The Cancer Genome Atlas data.
Conclusions:
- ErbB4 acts as a crucial protector against CAC development.
- ErbB4 deficiency promotes CAC by activating Kras through the upregulation of cholesterol metabolism.
- Targeting ErbB4 or related pathways may offer therapeutic strategies for CAC.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Negative Regulator Molecules
Regulation of Metabolism
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Regulated mRNA Transport
What is Metabolism?

